Shukra Medtech Q2 total income reaches Rs 44.78 crore
Key highlights
- Shukra Medtech reported Rs 44.78 crore of consolidated total income in the quarter ended September 30, 2026, versus Rs 7.59 crore a year earlier.
- Shukra Medtech’s consolidated net profit was Rs 12.71 crore in Q2 FY27, compared with Rs 2.38 crore in Q2 FY26.
- Shukra Medtech reported pharmaceutical and medtech segment revenue of Rs 32.27 crore and Rs 12.51 crore, respectively, in Q2 FY27.
- Shukra Medtech’s total assets were Rs 175.26 crore at September 30, 2026, compared with Rs 117.44 crore at March 31, 2026.
powered by IRIS

Shukra Medtech Limited reported consolidated total income of Rs 44.78 crore and net profit of Rs 12.71 crore for the quarter ended September 30, 2026, compared with Rs 7.59 crore and Rs 2.38 crore, respectively, a year earlier. Its board approved the unaudited consolidated results on November 4, 2026.
Know Shukra Medtech inside out
Results, valuation, peers and who's buying, in one view.
How did Shukra Medtech perform in the September 2026 quarter?
Shukra Medtech reported Rs 44.78 crore of total income in the quarter ended September 30, 2026, up from Rs 24.06 crore in the June 2026 quarter and Rs 7.59 crore in the September 2025 quarter. The September-quarter statement includes Rs 57.20 lakh of other income, while the segment disclosure lists total segment revenue of Rs 44.78 crore.
Net profit was Rs 12.71 crore, versus Rs 12.96 crore in the immediately preceding quarter and Rs 2.38 crore a year earlier. Therefore, profit was Rs 24.66 lakh lower quarter on quarter despite the increase in total income, while it was Rs 10.33 crore above the September 2025 result.
Shukra Medtech’s September-quarter expenses were Rs 26.95 crore, compared with Rs 7.39 crore in the year-earlier quarter. Cost of materials consumed was Rs 15.99 crore, employee-benefit expense was Rs 4.26 crore and other expenses were Rs 5.25 crore. Depreciation and amortisation amounted to Rs 1.12 crore, while finance cost was Rs 3.22 lakh.
Which segments produced Shukra Medtech’s quarterly revenue?
Shukra Medtech reported Rs 32.27 crore of pharmaceutical segment revenue and Rs 12.51 crore of medtech segment revenue for the September 2026 quarter. The two segments together accounted for Rs 44.78 crore of reported segment revenue, and the segment statement did not report inter-segment revenue.
Pharmaceutical segment revenue increased from Rs 24.06 crore in the June 2026 quarter and Rs 7.59 crore in the September 2025 quarter. The medtech segment had no revenue reported in either comparison quarter. The company said the Shukra MedTech segment name has been effective from October 1, 2025 onwards.
The pharmaceutical segment recorded profit before tax and interest of Rs 15.06 crore in the quarter, while the medtech segment recorded Rs 3.10 crore. Their combined segment result was Rs 18.16 crore, compared with consolidated profit before tax of Rs 17.83 crore after finance cost.
For the half year ended September 30, 2026, pharmaceutical revenue was Rs 56.33 crore and medtech revenue was Rs 12.51 crore, taking total segment revenue to Rs 68.84 crore. In the corresponding half year of 2025, the filing reported Rs 14.09 crore of pharmaceutical revenue and no medtech revenue.
What do Shukra Medtech’s half-year results show?
Shukra Medtech reported Rs 68.84 crore of consolidated total income and Rs 25.67 crore of net profit for the half year ended September 30, 2026. The corresponding figures for the half year ended September 30, 2025 were Rs 14.09 crore and Rs 3.41 crore, respectively.
Profit before tax rose to Rs 36.00 crore from Rs 1.57 crore in the prior-year half year. Current tax expense was Rs 10.55 crore, while deferred tax was a credit of Rs 92.31 lakh. Basic and diluted earnings per share were Rs 0.58, compared with Rs 0.08 in the corresponding 2025 period.
Six-month expenses were Rs 32.84 crore, compared with Rs 12.52 crore a year earlier. Material consumption was Rs 17.24 crore, employee-benefit expense was Rs 8.65 crore, depreciation and amortisation was Rs 2.20 crore, and other expenses were Rs 6.78 crore.
Paid-up equity share capital stood at Rs 48.08 crore at September 30, 2026, compared with Rs 43.79 crore at September 30, 2025. Shukra Medtech said it converted convertible warrants issued on a preferential basis in an earlier period into equity shares during the half year, increasing its share capital.
Got a follow-up? Ask IRIS
How did Shukra Medtech’s financial position change?
Shukra Medtech reported total assets of Rs 175.26 crore at September 30, 2026, compared with Rs 117.44 crore at March 31, 2026. Current assets were Rs 128.27 crore, including Rs 38.71 crore of trade receivables, Rs 23.42 crore of inventories and Rs 11.02 crore of cash and cash equivalents.
Capital work-in-progress increased to Rs 26.09 crore from Rs 11.91 crore at March 31, while property, plant and equipment declined to Rs 20.91 crore from Rs 21.72 crore. Total equity was Rs 118.54 crore at September 30, 2026, compared with Rs 80.85 crore at the preceding financial year-end.
Total liabilities rose to Rs 56.71 crore from Rs 27.59 crore over the same period. Current liabilities were Rs 45.78 crore, comprising Rs 12.87 crore of borrowings, Rs 12.86 crore of trade payables and Rs 18.04 crore of short-term provisions; non-current borrowings were Rs 9.63 crore, against Rs 3.19 crore at March 31.
What did Shukra Medtech report on cash flow and corporate matters?
Shukra Medtech generated net operating cash flow of Rs 43.31 lakh during the half year ended September 30, 2026. The cash-flow statement recorded increases of Rs 15.76 crore in trade receivables, Rs 9.51 crore in inventories and Rs 14.14 crore in other assets, partly offset by Rs 2.79 crore higher trade payables.
Investing activities used Rs 15.33 crore during the six months, while financing activities generated Rs 19.94 crore. Cash and cash equivalents consequently rose to Rs 11.02 crore at September 30, 2026, from Rs 5.98 crore at the beginning of the period.
Shukra Medtech changed its name from Shukra Pharmaceuticals Limited with effect from October 12, 2026. The company also reported zero investor complaints received and zero complaints pending during the half year ended September 30, 2026, and said prior-period figures were regrouped or reclassified where necessary.
Conclusion
Shukra Medtech’s September 2026 results showed higher consolidated income and profit against the September 2025 quarter, with the pharmaceutical segment contributing Rs 32.27 crore of quarterly revenue and the medtech segment contributing Rs 12.51 crore. However, quarterly net profit of Rs 12.71 crore was below the Rs 12.96 crore reported in the June 2026 quarter despite higher total income.
The next disclosures will show whether the Rs 38.71 crore trade-receivables balance, Rs 23.42 crore inventory balance and Rs 26.09 crore capital work-in-progress translate into cash generation. Investors can also track the effect of the completed preferential-warrant conversion, which increased paid-up equity share capital to Rs 48.08 crore at September 30, 2026.


